Header Logo

Connection

Mayer Davidson to Hypoglycemic Agents

Back to Details
This is a "connection" page, showing publications Mayer Davidson has written about Hypoglycemic Agents.
Mayer Davidson
Connection Strength
10.015
Hypoglycemic Agents
  1. Glycaemic treatment of newly diagnosed type 2 diabetes. Diabetes Obes Metab. 2024 Nov; 26(11):5492-5493.
    View in: PubMed
    Score: 0.796
  2. Real-world evidence for computerized insulin dose-adjustment algorithms in the effective use of continuous glucose monitoring by primary care clinicians. Diabetes Obes Metab. 2024 Aug; 26(8):3475-3477.
    View in: PubMed
    Score: 0.784
  3. Delayed response to an injection of U-500 regular insulin is not rare. J Diabetes. 2019 Jul; 11(7):519-521.
    View in: PubMed
    Score: 0.547
  4. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract. 2018 Jan; 135:102-110.
    View in: PubMed
    Score: 0.497
  5. Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. J Diabetes Complications. 2016 08; 30(6):981-5.
    View in: PubMed
    Score: 0.445
  6. Response to comment on Grunberger "insulin analogs-are they worth it? Yes!" Diabetes Care 2014;37:1767-1770 and Davidson "insulin analogs-is there a compelling case to use them? No!" Diabetes Care 2014;37:1771-1774. Diabetes Care. 2014 Oct; 37(10):e231.
    View in: PubMed
    Score: 0.400
  7. Insulin analogs--is there a compelling case to use them? No! Diabetes Care. 2014 Jun; 37(6):1771-4.
    View in: PubMed
    Score: 0.391
  8. Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. Endocr Pract. 2011 Sep-Oct; 17(5):691-8.
    View in: PubMed
    Score: 0.323
  9. Evaluation of self monitoring of blood glucose in non-insulin-treated diabetic patients by randomized controlled trials: little bang for the buck. Rev Recent Clin Trials. 2010 Sep; 5(3):138-42.
    View in: PubMed
    Score: 0.302
  10. Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation. Curr Opin Endocrinol Diabetes Obes. 2009 Apr; 16(2):107-12.
    View in: PubMed
    Score: 0.274
  11. Comparison of glyburide versus insulin in management of gestational diabetes mellitus. Endocr Pract. 2007 Jul-Aug; 13(4):427-8.
    View in: PubMed
    Score: 0.242
  12. Clinical implications of the DREAM Study. Diabetes Care. 2007 Feb; 30(2):418-20.
    View in: PubMed
    Score: 0.235
  13. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care. 2006 Nov; 29(11):2504-5.
    View in: PubMed
    Score: 0.231
  14. Starting insulin therapy in type 2 diabetic patients: does it really matter how? Diabetes Care. 2005 Feb; 28(2):494-5.
    View in: PubMed
    Score: 0.205
  15. Thiazolidinediones. N Engl J Med. 2005 Jan 13; 352(2):205-7; author reply 205-7.
    View in: PubMed
    Score: 0.204
  16. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population. Diabetes Care. 2004 Jul; 27(7):1741-2.
    View in: PubMed
    Score: 0.197
  17. Triple therapy: definitions, application, and treating to target. Diabetes Care. 2004 Jul; 27(7):1834-5.
    View in: PubMed
    Score: 0.197
  18. In adults with BMI =27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk. Ann Intern Med. 2023 11; 176(11):JC129.
    View in: PubMed
    Score: 0.188
  19. A simplified straightforward protocol for the use of U-500 regular insulin. Diabetes Obes Metab. 2023 02; 25(2):634-636.
    View in: PubMed
    Score: 0.176
  20. Treatment decisions for type 2 diabetes. JAMA. 2002 Apr 03; 287(13):1646-7; author reply 1647-8.
    View in: PubMed
    Score: 0.168
  21. Comment on Aleppo et al. The Effect of Discontinuing Continuous Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care 2021;44:2729-2737. Diabetes Care. 2022 04 01; 45(4):e84.
    View in: PubMed
    Score: 0.168
  22. Established therapies for diabetes mellitus. Curr Med Res Opin. 2002; 18 Suppl 1:s13-21.
    View in: PubMed
    Score: 0.166
  23. The "Cost-Effective" beneficial effect of pioglitazone on cardiovascular disease. Diabetes Res Clin Pract. 2020 07; 165:108223.
    View in: PubMed
    Score: 0.148
  24. Second-generation basal insulins to initiate insulin therapy in type 2 diabetes: A need for clinical evidence before incurring increased costs. Diabetes Obes Metab. 2020 05; 22(5):719-721.
    View in: PubMed
    Score: 0.146
  25. SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists. Ann Intern Med. 2019 12 17; 171(12):JC70.
    View in: PubMed
    Score: 0.144
  26. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes. 2020 Jan; 12(1):91-94.
    View in: PubMed
    Score: 0.142
  27. Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes. Ann Intern Med. 2019 04 16; 170(8):JC39.
    View in: PubMed
    Score: 0.137
  28. Effectiveness of certified diabetes educators following pre-approved protocols to redesign diabetes care delivery in primary care: Results of the REMEDIES 4D trial. Contemp Clin Trials. 2018 01; 64:201-209.
    View in: PubMed
    Score: 0.123
  29. Continuous Glucose Monitoring in Patients With Type 1 Diabetes Taking Insulin Injections. JAMA. 2017 01 24; 317(4):363-364.
    View in: PubMed
    Score: 0.118
  30. Treatment of non-insulin-dependent diabetes mellitus. Mayo Clin Proc. 1997 Jan; 72(1):92.
    View in: PubMed
    Score: 0.117
  31. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997 Jan; 102(1):99-110.
    View in: PubMed
    Score: 0.117
  32. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab. 1996 Jul; 81(7):2423-7.
    View in: PubMed
    Score: 0.113
  33. The reality of type 2 diabetes prevention. Diabetes Care. 2014 Apr; 37(4):943-9.
    View in: PubMed
    Score: 0.097
  34. Self-mixed/split insulin regimen: a serious omission in the ADA/EASD position statement. Diabetes Care. 2014; 37(1):3-4.
    View in: PubMed
    Score: 0.095
  35. Successful treatment of markedly symptomatic patients with type II diabetes mellitus using high doses of sulfonylurea agents. West J Med. 1992 Aug; 157(2):199-200.
    View in: PubMed
    Score: 0.086
  36. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med. 1991 Jul 01; 115(1):45-53.
    View in: PubMed
    Score: 0.080
  37. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract. 2011 May-Jun; 17(3):395-403.
    View in: PubMed
    Score: 0.079
  38. Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity. Diabetes. 1991 Apr; 40(4):492-8.
    View in: PubMed
    Score: 0.079
  39. Use of sulfonylurea agents in older diabetic patients. Clin Geriatr Med. 1990 Nov; 6(4):903-21.
    View in: PubMed
    Score: 0.076
  40. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care. 2010 Feb; 33(2):281-3.
    View in: PubMed
    Score: 0.071
  41. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009 Jan; 52(1):17-30.
    View in: PubMed
    Score: 0.066
  42. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan; 32(1):193-203.
    View in: PubMed
    Score: 0.066
  43. No need for the needle (at first). Diabetes Care. 2008 Oct; 31(10):2070-1.
    View in: PubMed
    Score: 0.066
  44. Use oral hypoglycemics with caution...but keep caution in context. Geriatrics. 1988 Aug; 43(8):83-4.
    View in: PubMed
    Score: 0.065
  45. Metformin does not suppress thyrotropin. Endocr Pract. 2008 Mar; 14(2):252-3.
    View in: PubMed
    Score: 0.063
  46. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia. 2008 Jan; 51(1):8-11.
    View in: PubMed
    Score: 0.063
  47. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008 Jan; 31(1):173-5.
    View in: PubMed
    Score: 0.063
  48. Effect of a nurse-directed diabetes disease management program on urgent care/emergency room visits and hospitalizations in a minority population. Diabetes Care. 2007 Feb; 30(2):224-7.
    View in: PubMed
    Score: 0.059
  49. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006 Aug; 49(8):1711-21.
    View in: PubMed
    Score: 0.057
  50. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes Care. 2006 Jun; 29(6):1395-6.
    View in: PubMed
    Score: 0.056
  51. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: response to Welschen et al. and Kleefstra et al. Diabetes Care. 2005 Oct; 28(10):2597; author reply 2597-8.
    View in: PubMed
    Score: 0.054
  52. Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care. 2005 Jan; 28(1):222-4.
    View in: PubMed
    Score: 0.051
  53. Indirect support for the use of supplemental insulin in hospitalized insulin-requiring diabetic patients. Diabetes Care. 2004 Sep; 27(9):2260-1.
    View in: PubMed
    Score: 0.050
  54. Effect of Pancreas Tonic (an ayurvedic herbal supplement) in type 2 diabetes mellitus. Metabolism. 2004 Sep; 53(9):1166-73.
    View in: PubMed
    Score: 0.050
  55. Quality of outpatient care provided to diabetic patients. A health maintenance organization experience. Diabetes Care. 1996 Jun; 19(6):601-6.
    View in: PubMed
    Score: 0.028
  56. Dexamethasone-induced impairment in skeletal muscle glucose transport is not reversed by inhibition of free fatty acid oxidation. Metabolism. 1996 Jan; 45(1):92-100.
    View in: PubMed
    Score: 0.027
  57. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ. 2012 Feb 27; 344:e486.
    View in: PubMed
    Score: 0.021
  58. Perioperative management of diabetes mellitus. Anesthesiology. 1981 Aug; 55(2):104-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.